Essential Partners’s Atrium Therapeutics RNA Stock Holding History

Essential Partners’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.87K	Buy	+288	New	+$3.76K	﹤0.01%	1659

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Essential Partners's RNA Position: Q2 2026 in Review

Essential Partners opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 288 shares worth $3.87K. The stake represents ﹤0.01% of the portfolio and ranks #1659 among its holdings.

155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Essential Partners held 288 shares of Atrium Therapeutics worth $3.87K as of Q2 2026.
Atrium Therapeutics was a new Essential Partners position in Q2 2026.
Atrium Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1659 holding.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.